Chimeric antigen receptor (CAR) T cells have shown great success in the treatment of CD19+ hematological malignancies. leading to their recent approval by the FDA as a new cancer treatment modality. However. their broad use is limited since a CAR targets a single tumor associated antigen (TAA). https://medilogices.shop/product-category/first-aid/